• Top stories in hematology/oncology: FDA decisions on drugs for prostate cancer, hemophilia A; biannual MRIs more effective than mammography

    2 monthes ago - By Healio

    Among the top stories in hematology and oncology this week were announcements that the FDA granted Rubraca its breakthrough therapy designation for some patients with prostate cancer and also approved Hemlibra for certain patients with hemophilia A.
    Other popular stories included a study that concluded twice-a-year MRIs were more effective than mammograms in high-risk women, data that indicated e-cigarette use doubled the risk for myocardial infarctions and a review of the groundbreaking research in cancer immunotherapy that was recognized with this year's Nobel Prizes in medicine.
    Read more ...